Skip to Content

Tengion to Present Preclinical Data For Regeneration of Entire Bladder

Preclinical Results to be Presented During May 18 Press Briefing and Poster Session

EAST NORRITON, Pa., May 12, 2008 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-vessels, today announced that it will present preclinical efficacy data for its Tengion Neo-Bladder Replacement(TM) at the Annual Meeting of the American Urological Association (AUA) in Orlando, Florida, May 17-22, 2008.

Tim Bertram, D.V.M., Ph.D., Senior Vice President, Science and Technology of Tengion, was amongst a select group of scientists requested to present both at a poster session and during a press briefing sponsored by the AUA. Dr. Bertram is scheduled to present "Total Regenerated Urinary Bladders are Structurally and Pharmacologically Similar to Native Tissue" (Abstract 215) during the AUA Press Briefing at 9:30 a.m. EDT and the AUA Poster Session following from 10:30 a.m. to 12:30 p.m. EDT on May 18, 2008.

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo- tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at:

CONTACT: Gary Sender of Tengion Inc., +1-267-960-4802; Keri Mattox of PureCommunications, +1-215-791-0105

Web site:

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2008